China SXT Pharmaceuticals (NASDAQ:SXTC) Hits New 1-Year Low - Here's What Happened

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $3.96 and last traded at $3.8530, with a volume of 155008 shares traded. The stock had previously closed at $4.53.Wall Street Analyst Weigh InSeparately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of "Sell".Get Our Latest Report on SXTCChina SXT Pharmaceuticals Stock PerformanceThe firm has a 50 day moving average price of $149.19 and a two-hundred day moving average price of $202.13. China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter. Institutional Inflows and OutflowsAn institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC increased its holdings in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Free Report) by 107.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,983 shares of the company's stock after buying an additional 15,013 shares during the period. Virtu Financial LLC's holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. 5.02% of the stock is currently owned by hedge funds and other institutional investors. China SXT Pharmaceuticals Company Profile (Get Free Report)China SXT Pharmaceuticals Inc NASDAQ: SXTC is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets. The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.See AlsoFive stocks we like better than China SXT PharmaceuticalsWall Street Turns Bullish on USAU as Gold Hits New Record!Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It“Fed Proof” Your Bank Account with THESE 4 Simple StepsWhat a Former CIA Agent Knows About the Coming CollapseNEW LAW: Congress Approves Setup For Digital Dollar?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?Before you consider China SXT Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here